drugset
drugset / Trial / NCT07125755

Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma

NCT07125755 ↗

Phase 3 Recruiting 386 enrolled Sun Yat-sen University
RandomizedParallel-groupDouble-blindTreatment

Summary

The main objective of this trial was to determine the value of concurrent chemoradiotherapy for Intermediate-risk head and neck squamous cell carcinoma

Timeline

Start
2025-08-15
Primary completion
2028-08-15
Completion
2031-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 100 mg/m2 Intravenous

Indications

head and neck squamous cell carcinoma